SCHEMBL20153137

SCHEMBL20153137

CCC(C)Cc1nccn1C

nearest known ligand 0.40

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
FDPS P14324 1/20 0.40
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
TSHR P16473 1/20 0.38
OPRK1 P41145 1/20 0.38
LPO P22079 1/20 0.38
CHRNB2 P17787 1/20 0.36
CHRNA4 P43681 1/20 0.36
HTT P42858 1/20 0.35
L3MBTL1 Q9Y468 2/20 0.33
MAPK1 P28482 1/20 0.33
ALDH1A1 P00352 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
LMNA P02545 1/20 0.33
CBLB Q13191 2/20 0.32
MLYCD O95822 1/20 0.32
TRPM5 Q9NZQ8 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3979171 0.82 FDPS (0.43) FDPSMEN1KMT2ATSHROPRK1
Hydrochloric Acid SCHEMBL16540554 0.80 TSHR (0.43) FDPSMEN1KMT2ATSHROPRK1
SCHEMBL13916698 0.79 FDPS (0.44) FDPSMEN1KMT2ATSHROPRK1
SCHEMBL12471254 0.79 FDPS (0.42) FDPSMEN1KMT2ATSHROPRK1
SCHEMBL21153907 0.78 FDPS (0.41) FDPSMEN1KMT2ATSHROPRK1
SCHEMBL6242617 0.78 FDPS (0.45) FDPSMEN1KMT2ATSHROPRK1
SCHEMBL27787033 0.78 FDPS (0.41) FDPSMEN1KMT2ATSHROPRK1
SCHEMBL12470714 0.77 MEN1 (0.38) FDPSMEN1KMT2ATSHROPRK1
SCHEMBL1155954 0.76 FDPS (0.39) FDPSMEN1KMT2ATSHROPRK1
SCHEMBL12471180 0.76 MEN1 (0.43) FDPSMEN1KMT2ATSHROPRK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3753939-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS Array Biopharma Inc. (US) 2020-12-23 EP disclosed
US-20180133200-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC. 2018-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180133200-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS RET, ROR1, BRAF FDPS 3973/4885MEN1 680/4885KMT2A 1171/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.